An 8-week randomized double-blind trial compared GHK-Cu in a nano-lipid carrier against Matrixyl 3000 and found a 55.8% reduction in wrinkle volume versus control serum, along with a 32.8% reduction in wrinkle depth
Common ones reported by the Government of Canada include nausea, vomiting, diarrhea, and loss of appetite, especially when starting the medication or increasing the dose
For hematocrit and reticulocyte counts, recommendations are to repeat these tests daily from the 5th to 7th days of treatment and then frequently until the hematocrit returns to a normal range (11, 14, 15)
It does not establish cellular uptake, tissue distribution, duration, target engagement, or clinical effectiveness
for the category, see Growth Hormone Secretagogues Explained
shown are the GLP-1-bound (orange) and TT-OAD2 bound (blue) GLP-1R